S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.02 (+0.92%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.57 (+0.72%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,197.04 (+0.38%)
TSLA   585.85 (+2.06%)
NVDA   530.10 (+0.13%)
BABA   276.50 (-0.44%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.07 (+1.01%)
AMD   87.18 (+0.54%)
T   29.03 (+0.14%)
NIO   54.16 (+0.88%)
F   9.10 (+0.22%)
ACB   10.45 (+19.98%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.02 (+0.92%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.57 (+0.72%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,197.04 (+0.38%)
TSLA   585.85 (+2.06%)
NVDA   530.10 (+0.13%)
BABA   276.50 (-0.44%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.07 (+1.01%)
AMD   87.18 (+0.54%)
T   29.03 (+0.14%)
NIO   54.16 (+0.88%)
F   9.10 (+0.22%)
ACB   10.45 (+19.98%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.02 (+0.92%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.57 (+0.72%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,197.04 (+0.38%)
TSLA   585.85 (+2.06%)
NVDA   530.10 (+0.13%)
BABA   276.50 (-0.44%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.07 (+1.01%)
AMD   87.18 (+0.54%)
T   29.03 (+0.14%)
NIO   54.16 (+0.88%)
F   9.10 (+0.22%)
ACB   10.45 (+19.98%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.02 (+0.92%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.57 (+0.72%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,197.04 (+0.38%)
TSLA   585.85 (+2.06%)
NVDA   530.10 (+0.13%)
BABA   276.50 (-0.44%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.07 (+1.01%)
AMD   87.18 (+0.54%)
T   29.03 (+0.14%)
NIO   54.16 (+0.88%)
F   9.10 (+0.22%)
ACB   10.45 (+19.98%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
Log in
NASDAQ:STSA

Satsuma Pharmaceuticals Competitors

$4.68
+0.14 (+3.08 %)
(As of 11/27/2020 12:59 PM ET)
Add
Compare
Today's Range
$4.63
Now: $4.68
$4.84
50-Day Range
$3.56
MA: $4.03
$4.54
52-Week Range
$3.50
Now: $4.68
$36.10
Volume11,406 shs
Average Volume739,223 shs
Market Capitalization$81.53 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Satsuma Pharmaceuticals (NASDAQ:STSA) Vs. TFC, PNC, FRC, FITB, SIVB, and KEY

Should you be buying STSA stock or one of its competitors? Companies in the sub-industry of "regional banks" are considered alternatives and competitors to Satsuma Pharmaceuticals, including Truist Financial (TFC), The PNC Financial Services Group (PNC), First Republic Bank (FRC), Fifth Third Bancorp (FITB), SVB Financial Group (SIVB), and KeyCorp (KEY).

Satsuma Pharmaceuticals (NASDAQ:STSA) and Truist Financial (NYSE:TFC) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Profitability

This table compares Satsuma Pharmaceuticals and Truist Financial's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Satsuma PharmaceuticalsN/A-40.33%-36.87%
Truist Financial16.95%7.76%0.96%

Valuation and Earnings

This table compares Satsuma Pharmaceuticals and Truist Financial's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Satsuma PharmaceuticalsN/AN/A$-28,170,000.00($4.80)-0.98
Truist Financial$14.66 billion4.45$3.22 billion$4.3711.09

Truist Financial has higher revenue and earnings than Satsuma Pharmaceuticals. Satsuma Pharmaceuticals is trading at a lower price-to-earnings ratio than Truist Financial, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

79.1% of Satsuma Pharmaceuticals shares are owned by institutional investors. Comparatively, 73.4% of Truist Financial shares are owned by institutional investors. 45.7% of Satsuma Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Truist Financial shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Satsuma Pharmaceuticals and Truist Financial, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Satsuma Pharmaceuticals12102.00
Truist Financial081202.60

Satsuma Pharmaceuticals currently has a consensus target price of $4.6250, indicating a potential downside of 1.18%. Truist Financial has a consensus target price of $45.0789, indicating a potential downside of 6.96%. Given Satsuma Pharmaceuticals' higher possible upside, research analysts clearly believe Satsuma Pharmaceuticals is more favorable than Truist Financial.

Summary

Truist Financial beats Satsuma Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

Satsuma Pharmaceuticals (NASDAQ:STSA) and The PNC Financial Services Group (NYSE:PNC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.

Profitability

This table compares Satsuma Pharmaceuticals and The PNC Financial Services Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Satsuma PharmaceuticalsN/A-40.33%-36.87%
The PNC Financial Services Group38.16%5.97%0.69%

Analyst Ratings

This is a summary of recent ratings and price targets for Satsuma Pharmaceuticals and The PNC Financial Services Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Satsuma Pharmaceuticals12102.00
The PNC Financial Services Group110802.37

Satsuma Pharmaceuticals currently has a consensus target price of $4.6250, indicating a potential downside of 1.18%. The PNC Financial Services Group has a consensus target price of $128.40, indicating a potential downside of 8.16%. Given Satsuma Pharmaceuticals' higher probable upside, equities research analysts clearly believe Satsuma Pharmaceuticals is more favorable than The PNC Financial Services Group.

Institutional and Insider Ownership

79.1% of Satsuma Pharmaceuticals shares are held by institutional investors. Comparatively, 79.5% of The PNC Financial Services Group shares are held by institutional investors. 45.7% of Satsuma Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of The PNC Financial Services Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Satsuma Pharmaceuticals and The PNC Financial Services Group's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Satsuma PharmaceuticalsN/AN/A$-28,170,000.00($4.80)-0.98
The PNC Financial Services Group$21.62 billion2.74$5.37 billion$11.3912.27

The PNC Financial Services Group has higher revenue and earnings than Satsuma Pharmaceuticals. Satsuma Pharmaceuticals is trading at a lower price-to-earnings ratio than The PNC Financial Services Group, indicating that it is currently the more affordable of the two stocks.

Summary

The PNC Financial Services Group beats Satsuma Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

First Republic Bank (NYSE:FRC) and Satsuma Pharmaceuticals (NASDAQ:STSA) are both finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Analyst Ratings

This is a summary of current ratings and recommmendations for First Republic Bank and Satsuma Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
First Republic Bank19702.35
Satsuma Pharmaceuticals12102.00

First Republic Bank presently has a consensus price target of $123.3750, suggesting a potential downside of 5.45%. Satsuma Pharmaceuticals has a consensus price target of $4.6250, suggesting a potential downside of 1.18%. Given Satsuma Pharmaceuticals' higher possible upside, analysts plainly believe Satsuma Pharmaceuticals is more favorable than First Republic Bank.

Valuation and Earnings

This table compares First Republic Bank and Satsuma Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
First Republic Bank$4.16 billion5.41$930.33 million$5.2025.09
Satsuma PharmaceuticalsN/AN/A$-28,170,000.00($4.80)-0.98

First Republic Bank has higher revenue and earnings than Satsuma Pharmaceuticals. Satsuma Pharmaceuticals is trading at a lower price-to-earnings ratio than First Republic Bank, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares First Republic Bank and Satsuma Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
First Republic Bank22.95%10.96%0.81%
Satsuma PharmaceuticalsN/A-40.33%-36.87%

Institutional and Insider Ownership

95.7% of First Republic Bank shares are owned by institutional investors. Comparatively, 79.1% of Satsuma Pharmaceuticals shares are owned by institutional investors. 45.7% of Satsuma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

First Republic Bank beats Satsuma Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

Satsuma Pharmaceuticals (NASDAQ:STSA) and Fifth Third Bancorp (NASDAQ:FITB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Earnings and Valuation

This table compares Satsuma Pharmaceuticals and Fifth Third Bancorp's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Satsuma PharmaceuticalsN/AN/A$-28,170,000.00($4.80)-0.98
Fifth Third Bancorp$9.79 billion1.91$2.51 billion$2.779.48

Fifth Third Bancorp has higher revenue and earnings than Satsuma Pharmaceuticals. Satsuma Pharmaceuticals is trading at a lower price-to-earnings ratio than Fifth Third Bancorp, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Satsuma Pharmaceuticals and Fifth Third Bancorp, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Satsuma Pharmaceuticals12102.00
Fifth Third Bancorp171002.50

Satsuma Pharmaceuticals currently has a consensus target price of $4.6250, indicating a potential downside of 1.18%. Fifth Third Bancorp has a consensus target price of $23.85, indicating a potential downside of 9.14%. Given Satsuma Pharmaceuticals' higher possible upside, analysts clearly believe Satsuma Pharmaceuticals is more favorable than Fifth Third Bancorp.

Profitability

This table compares Satsuma Pharmaceuticals and Fifth Third Bancorp's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Satsuma PharmaceuticalsN/A-40.33%-36.87%
Fifth Third Bancorp17.50%7.52%0.80%

Institutional and Insider Ownership

79.1% of Satsuma Pharmaceuticals shares are held by institutional investors. Comparatively, 78.5% of Fifth Third Bancorp shares are held by institutional investors. 45.7% of Satsuma Pharmaceuticals shares are held by company insiders. Comparatively, 0.5% of Fifth Third Bancorp shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Fifth Third Bancorp beats Satsuma Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

Satsuma Pharmaceuticals (NASDAQ:STSA) and SVB Financial Group (NASDAQ:SIVB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.

Valuation & Earnings

This table compares Satsuma Pharmaceuticals and SVB Financial Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Satsuma PharmaceuticalsN/AN/A$-28,170,000.00($4.80)-0.98
SVB Financial Group$3.53 billion5.19$1.14 billion$21.7316.28

SVB Financial Group has higher revenue and earnings than Satsuma Pharmaceuticals. Satsuma Pharmaceuticals is trading at a lower price-to-earnings ratio than SVB Financial Group, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Satsuma Pharmaceuticals and SVB Financial Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Satsuma Pharmaceuticals12102.00
SVB Financial Group141002.60

Satsuma Pharmaceuticals currently has a consensus price target of $4.6250, indicating a potential downside of 1.18%. SVB Financial Group has a consensus price target of $257.7333, indicating a potential downside of 27.15%. Given Satsuma Pharmaceuticals' higher probable upside, equities research analysts plainly believe Satsuma Pharmaceuticals is more favorable than SVB Financial Group.

Profitability

This table compares Satsuma Pharmaceuticals and SVB Financial Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Satsuma PharmaceuticalsN/A-40.33%-36.87%
SVB Financial Group25.26%13.61%1.19%

Institutional and Insider Ownership

79.1% of Satsuma Pharmaceuticals shares are held by institutional investors. Comparatively, 90.0% of SVB Financial Group shares are held by institutional investors. 45.7% of Satsuma Pharmaceuticals shares are held by insiders. Comparatively, 0.8% of SVB Financial Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

SVB Financial Group beats Satsuma Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

KeyCorp (NYSE:KEY) and Satsuma Pharmaceuticals (NASDAQ:STSA) are both finance companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares KeyCorp and Satsuma Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
KeyCorp16.38%7.87%0.76%
Satsuma PharmaceuticalsN/A-40.33%-36.87%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for KeyCorp and Satsuma Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
KeyCorp411402.00
Satsuma Pharmaceuticals12102.00

KeyCorp presently has a consensus price target of $18.2833, indicating a potential upside of 11.96%. Satsuma Pharmaceuticals has a consensus price target of $4.6250, indicating a potential downside of 1.18%. Given KeyCorp's higher probable upside, analysts plainly believe KeyCorp is more favorable than Satsuma Pharmaceuticals.

Institutional & Insider Ownership

79.7% of KeyCorp shares are owned by institutional investors. Comparatively, 79.1% of Satsuma Pharmaceuticals shares are owned by institutional investors. 0.7% of KeyCorp shares are owned by insiders. Comparatively, 45.7% of Satsuma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares KeyCorp and Satsuma Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KeyCorp$7.69 billion2.07$1.72 billion$1.809.07
Satsuma PharmaceuticalsN/AN/A$-28,170,000.00($4.80)-0.98

KeyCorp has higher revenue and earnings than Satsuma Pharmaceuticals. Satsuma Pharmaceuticals is trading at a lower price-to-earnings ratio than KeyCorp, indicating that it is currently the more affordable of the two stocks.

Summary

KeyCorp beats Satsuma Pharmaceuticals on 10 of the 11 factors compared between the two stocks.


Satsuma Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Truist Financial logo
TFC
Truist Financial
1.8$48.45+0.1%$65.40 billion$14.66 billion16.48
The PNC Financial Services Group logo
PNC
The PNC Financial Services Group
2.5$139.81+0.6%$59.59 billion$21.62 billion8.37Analyst Revision
First Republic Bank logo
FRC
First Republic Bank
1.9$130.49+1.9%$22.89 billion$4.16 billion23.30
Fifth Third Bancorp logo
FITB
Fifth Third Bancorp
2.5$26.25+1.6%$19.01 billion$9.79 billion13.06Insider Selling
SVB Financial Group logo
SIVB
SVB Financial Group
1.6$353.79+0.2%$18.37 billion$3.53 billion20.59
KeyCorp logo
KEY
KeyCorp
2.9$16.33+1.1%$16.12 billion$7.69 billion14.20Analyst Upgrade
M&T Bank logo
MTB
M&T Bank
2.0$121.23+0.9%$15.69 billion$6.94 billion12.10
Regions Financial logo
RF
Regions Financial
2.4$15.62+0.8%$15.13 billion$6.76 billion19.77
Huntington Bancshares logo
HBAN
Huntington Bancshares
2.2$12.47+1.8%$12.91 billion$5.66 billion17.56
Commerce Bancshares logo
CBSH
Commerce Bancshares
1.5$68.04+1.5%$7.70 billion$1.45 billion24.13
First Horizon National logo
FHN
First Horizon National
2.4$12.72+1.7%$7.17 billion$2.28 billion8.31Insider Selling
Zions Bancorporation, National Association logo
ZION
Zions Bancorporation, National Association
2.4$39.46+3.8%$6.72 billion$3.25 billion16.72
East West Bancorp logo
EWBC
East West Bancorp
2.6$43.79+4.0%$6.45 billion$2.09 billion10.65Analyst Upgrade
Signature Bank logo
SBNY
Signature Bank
2.8$115.30+0.0%$6.17 billion$1.94 billion12.15Analyst Report
Prosperity Bancshares logo
PB
Prosperity Bancshares
2.0$64.67+0.2%$5.98 billion$957.22 million12.93
Cullen/Frost Bankers logo
CFR
Cullen/Frost Bankers
2.2$87.32+0.6%$5.64 billion$1.50 billion16.41
Western Alliance Bancorporation logo
WAL
Western Alliance Bancorporation
2.3$54.46+1.3%$5.56 billion$1.29 billion12.81
TCF Financial logo
TCF
TCF Financial
2.0$35.32+1.9%$5.49 billion$1.61 billion18.59
First Citizens BancShares logo
FCNCA
First Citizens BancShares
0.9$542.60+2.1%$5.44 billion$1.82 billion12.39
BOK Financial logo
BOKF
BOK Financial
2.4$70.16+0.9%$5.12 billion$2.23 billion12.64
South State logo
SSB
South State
1.9$70.52+1.0%$5.05 billion$734.39 million41.48Insider Selling
Synovus Financial logo
SNV
Synovus Financial
2.2$32.81+1.6%$4.93 billion$2.41 billion14.27
First Financial Bankshares logo
FFIN
First Financial Bankshares
1.2$34.26+0.8%$4.91 billion$427.62 million26.15Insider Selling
Pinnacle Financial Partners logo
PNFP
Pinnacle Financial Partners
2.0$56.73+1.0%$4.35 billion$1.33 billion14.62
Popular logo
BPOP
Popular
2.1$50.78+1.4%$4.34 billion$2.83 billion9.10Dividend Announcement
Glacier Bancorp logo
GBCI
Glacier Bancorp
1.7$42.40+2.5%$4.14 billion$676.95 million16.63
United Bankshares logo
UBSI
United Bankshares
2.0$30.29+1.0%$3.97 billion$913.05 million14.36Dividend Announcement
Insider Selling
Valley National Bancorp logo
VLY
Valley National Bancorp
1.3$9.50+1.7%$3.90 billionN/A0.00Dividend Announcement
Webster Financial logo
WBS
Webster Financial
2.2$39.75+0.8%$3.62 billion$1.44 billion13.61
Community Bank System logo
CBU
Community Bank System
1.2$64.85+1.4%$3.59 billion$616.35 million21.40Insider Selling
CIT Group logo
CIT
CIT Group
1.9$34.51+1.4%$3.49 billion$3.29 billion-6.54
UMB Financial logo
UMBF
UMB Financial
2.0$70.71+0.8%$3.42 billion$1.29 billion18.56
Wintrust Financial logo
WTFC
Wintrust Financial
2.4$57.66+1.8%$3.38 billion$1.79 billion12.78Analyst Downgrade
Insider Selling
Sterling Bancorp logo
STL
Sterling Bancorp
2.6$16.85+0.4%$3.29 billion$1.33 billion11.87
Umpqua logo
UMPQ
Umpqua
2.3$14.57+1.4%$3.25 billion$1.47 billion16.75
Home Bancshares, Inc. (Conway, AR) logo
HOMB
Home Bancshares, Inc. (Conway, AR)
2.0$19.35+1.3%$3.24 billion$817.50 million15.60Heavy News Reporting
Bank of Hawaii logo
BOH
Bank of Hawaii
2.1$77.67+2.1%$3.15 billion$770.73 million18.28
F.N.B. logo
FNB
F.N.B.
2.3$9.22+1.0%$3.00 billion$1.54 billion9.91Analyst Downgrade
PacWest Bancorp logo
PACW
PacWest Bancorp
2.1$24.77+3.6%$3.00 billion$1.36 billion-2.34
Texas Capital Bancshares logo
TCBI
Texas Capital Bancshares
1.5$57.37+0.1%$2.90 billion$1.46 billion28.54
BancorpSouth Bank logo
BXS
BancorpSouth Bank
1.5$26.47+2.0%$2.84 billion$1.06 billion12.60
CVB Financial logo
CVBF
CVB Financial
1.5$19.99+1.6%$2.81 billion$516.89 million15.38
BankUnited logo
BKU
BankUnited
2.5$30.14+0.7%$2.80 billion$1.43 billion14.49Insider Selling
Old National Bancorp logo
ONB
Old National Bancorp
1.8$16.52+1.6%$2.78 billion$929.70 million13.65Unusual Options Activity
First Interstate BancSystem logo
FIBK
First Interstate BancSystem
1.6$39.83+1.9%$2.56 billion$703.90 million15.38
Columbia Banking System logo
COLB
Columbia Banking System
1.6$33.53+2.4%$2.52 billion$627.13 million16.85
Investors Bancorp logo
ISBC
Investors Bancorp
2.2$9.95+0.7%$2.50 billion$1.09 billion12.28
Ameris Bancorp logo
ABCB
Ameris Bancorp
2.0$35.29+1.2%$2.49 billion$834.51 million10.69
Cathay General Bancorp logo
CATY
Cathay General Bancorp
1.7$30.39+1.2%$2.48 billion$814.02 million10.78Dividend Announcement
Independent Bank logo
INDB
Independent Bank
2.0$71.28+0.3%$2.34 billion$562.31 million17.91
This page was last updated on 11/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.